News
-
-
-
-
-
PRESS RELEASE
Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Research analysis reveals the effectiveness of mitochondrial transplantation in increasing tumour cell sensitivity to chemotherapy, confirming Vidac Pharma's innovative approach. Buy recommendation maintained for Vidac Pharma -
PRESS RELEASE
5E Advanced Materials Announces Pricing of $8.31 Million Public Offering of Common Stock
5E Advanced Materials, Inc. announces pricing of underwritten public offering of common stock in the United States to raise approximately $8.31 million. Offering expected to close on August 25, 2025 -
-
-
-
PRESS RELEASE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
ABIONYX Pharma discloses monthly statement of total voting rights and shares on Euronext Paris. Company focused on innovative medicines in rare diseases